Category: piperazines

Beiginejad, Hadi; Rafiee, Zeinab published an article in , the title of the article was Dependence of mechanisms to thermodynamics in the electrochemical study of different electrophiles in the presence of some sulfur nucleophiles.SDS of cas: 67914-60-7 And the article contains the following content:

Abstract: Electrochem. study of different electrophiles in the presence of p-toluenesulfinic acid and 2-mercaptobenzothiazole as sulfur nucleophiles was investigated. Mechanistic study of the electrochem. reactions indicates that the electrochem. oxidation of some species in the presence of the sulfur groups has different mechanisms, but some other species in the presence of both sulfur nucleophiles have the same mechanism. To explain the reason for this difference, the computational study was used. Thermodn. investigation shows that when ΔGtot of the electrochem. oxidation of products are less than that of initial species, the electrochem. produced species can be oxidized during controlled-potential coulometry. The results of this work indicate that the computational study can be used to justify the reaction mechanisms. Cyclic voltammetry, linear sweep voltammetry, and controlled-potential coulometry were used to obtain the exptl. results. Also, by the use of BP86 level of theory and 6-31 + G(d,p) basis set, the theor. data were obtained. The experimental process involved the reaction of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone(cas: 67914-60-7).SDS of cas: 67914-60-7

The Article related to electrophile isulfur nucleophile electrochem oxidation reaction mechanism, Placeholder for records without volume info and other aspects.SDS of cas: 67914-60-7

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Vener, Claudia; Banzi, Rita; Ambrogi, Federico; Ferrero, Annalisa; Saglio, Giuseppe; Pravettoni, Gabriella; Sant, Milena published an article in 2020, the title of the article was First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis.Product Details of 380843-75-4 And the article contains the following content:

Meta-anal. of. Imatinib, the first tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML), improves overall survival (OS), but the introduction of newer TKIs requires the definition of the optimal first-line TKI for newly diagnosed Philadelphia chromosome-pos. (Ph+) chronic-phase CML. This systematic review of randomized controlled trials compares the efficacy and safety of imatinib vs second-generation (dasatinib, nilotinib, bosutinib) and third-generation TKIs (ponatinib) in adults with newly diagnosed Ph+ CP CML, concentrating on OS, progression-free survival, and hematol. and nonhematol. adverse events. The quality of the evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation method. Two RCTs (imatinib vs nilotinib and imatinib vs dasatinib) found no difference in 5-yr OS or PFS. Second- and third-generation TKIs improved 3-mo major mol. responses (relative risk, 4.28; 95% confidence interval [RR], and other efficacy outcomes, decreased accelerated/blastic-phase transformations, but were associated with more cases of thrombocytopenia cardiovascular events and pancreatic and hepatic effects. GRADE showed that the certainty of the evidence ranged from high to moderate. This study shows that, in comparison with imatinib, second- and third-generation TKIs improve clin. responses, but the safer toxicity profile of imatinib may make it a better option for patients with comorbidities. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Product Details of 380843-75-4

The Article related to meta analysis chronic myeloid leukemia tki imatinib dasatinib ponatinib, Placeholder for records without volume info and other aspects.Product Details of 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 17, 2022, Lodha, Kamlesh K.; Wavhal, Deepak S.; Bhalekar, Sujit B.; Meshram, Rohan J.; Shinde, Vaishali S. published an article.Computed Properties of 67914-60-7 The title of the article was Exploring new tetrahydrothienopyridine derivatives as platelet agglutination inhibitors: synthesis, biological evaluation and In silico study. And the article contained the following:

The P2Y12 receptor is the major target for antithrombic drugs which plays a key role in platelet activation. New derivatives of 4,5,6,7-tetrahydrothieno[3,2-c]pyridine (THP) were designed targeting P2Y12 receptor. An efficient route was developed for synthesis of THP derivatives and subsequently evaluated for their antiplatelet agglutination activity. Amongst the synthesized THP derivatives (4 a-4 g), the compounds 4 a and 4 g displayed significant activity (with 88.25 and 70.17 % inhibition) as compared to other analogs and comparable with that of the reference drugs, aspirin and prasugrel. Data extracted from computational chem. techniques such as mol. docking, provided the structural rationale for the observed platelet agglutination inhibition by the newly synthesized tetrahydrothienopyridine analogs. We proposed the involvement of residues such as Cys-194 in the formation of the covalent adduct with the active metabolite of tetrahydrothienopyridine derivatives This study also put forward the possibility of the existence of an alternate pathway for metabolizing the tetrahydrothienopyridine compounds The structural data presented in this study is expected to accelerate the research on developing a tetrahydrothienopyridine scaffold as an effective antithrombotic therapeutic modality. The experimental process involved the reaction of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone(cas: 67914-60-7).Computed Properties of 67914-60-7

The Article related to platelet agglutination tetrahydrothienopyridine screening antiplatelet, Placeholder for records without volume info and other aspects.Computed Properties of 67914-60-7

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Jabbour, Elias; Kantarjian, Hagop published an article in 2020, the title of the article was Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.Reference of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile And the article contains the following content:

A review. Disease overview : Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1-2 cases per 100 000 adults. It accounts for approx. 15% of newly diagnosed cases of leukemia in adults. Diagnosis : CML is characterized by a balanced genetic translocation, t(9;22)(q34;q11.2), involving a fusion of the Abelson gene (ABL1) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. The mol. consequence of this translocation is the generation of a BCR-ABL1 fusion oncogene, which in turn translates into a BCR-ABL oncoprotein. Frontline therapy : Four tyrosine kinase inhibitors (TKIs), imatinib, nilotinib, dasatinib, and bosutinib are approved by the United States Food and Drug Administration for first-line treatment of newly diagnosed CML in chronic phase (CML-CP). Clin. trials with second generation TKIs reported significantly deeper and faster responses, but they had no impact on survival prolongation, likely because of the existence of highly effective salvage therapies for patients who have a cytogenetic relapse with frontline TKI. Salvage Therapy : For CML post failure on frontline therapy, second-line options include second and third generation TKIs. Although potent and selective, these exhibit unique pharmacol. profiles and response patterns relative to different patient and disease characteristics, such as patients′ comorbidities, disease stage, and BCR-ABL1 mutational status. Patients who develop the T315I “gatekeeper” mutation display resistance to all currently available TKIs except ponatinib. Allogeneic stem cell transplantation remains an important therapeutic option for patients with CML-CP who have failed at least 2 TKIs, and for all patients in advanced phase disease. Even among older patients who have a cytogenetic relapse post failure on all TKIs, they can maintain long-term survival if they continue on a daily most effective/less toxic TKI, with or without the addition of non-TKI anti-CML agents (hydroxyurea, omacetaxine, azacitidine, decitabine, cytarabine, busulfan, others). The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Reference of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to review imatinib dasatinib anticancer agent chronic myeloid leukemia, Placeholder for records without volume info and other aspects.Reference of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On April 30, 2020, Hochhaus, A.; Baccarani, M.; Silver, R. T.; Schiffer, C.; Apperley, J. F.; Cervantes, F.; Clark, R. E.; Cortes, J. E.; Deininger, M. W.; Guilhot, F.; Hjorth-Hansen, H.; Hughes, T. P.; Janssen, J. J. W. M.; Kantarjian, H. M.; Kim, D. W.; Larson, R. A.; Lipton, J. H.; Mahon, F. X.; Mayer, J.; Nicolini, F.; Niederwieser, D.; Pane, F.; Radich, J. P.; Rea, D.; Richter, J.; Rosti, G.; Rousselot, P.; Saglio, G.; Saussele, S.; Soverini, S.; Steegmann, J. L.; Turkina, A.; Zaritskey, A.; Hehlmann, R. published an article.Name: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. And the article contained the following:

A review. Abstract: The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving a stable deep mol. response (DMR) and discontinuing medication for treatment-free remission (TFR). The European LeukemiaNet convened an expert panel to critically evaluate and update the evidence to achieve these goals since its previous recommendations. First-line treatment is a tyrosine kinase inhibitor (TKI; imatinib brand or generic, dasatinib, nilotinib, and bosutinib are available first-line). Generic imatinib is the cost-effective initial treatment in CP. Various contraindications and side-effects of all TKIs should be considered. Patient risk status at diagnosis should be assessed with the new EUTOS long-term survival (ELTS)-score. Monitoring of response should be done by quant. polymerase chain reaction whenever possible. A change of treatment is recommended when intolerance cannot be ameliorated or when mol. milestones are not reached. Greater than 10% BCR-ABL1 at 3 mo indicates treatment failure when confirmed. Allogeneic transplantation continues to be a therapeutic option particularly for advanced phase CML. TKI treatment should be withheld during pregnancy. Treatment discontinuation may be considered in patients with durable DMR with the goal of achieving TFR. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Name: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to review imatinib dasatinib anticancer agent chronic myeloid leukemia, Placeholder for records without volume info and other aspects.Name: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On May 15, 2020, Kim, Jeong Hyeon; Han, Hyo Won; Han, Hyeong Jun published a patent.Category: piperazines The title of the patent was Infectious disease-treating drug screening method based on pluripotent stem cell-derived macrophages. And the patent contained the following:

The infectious disease-treating or preventing drug screening method uses pluripotent stem cell-derived macrophages (eMAC) with more similar gene expression with macrophages (hMDM) in human blood as compared with existing mouse-derived cell line (Raw264.7) and human-derived macrophage cell line (ThP-1) used for screening tuberculostatic drug. The screening method has an excellent screening effect when compared with the conventional screening methods. A tuberculostatic drug screening method that can be useful for new drug development and quality control of existing tuberculostatic drugs is provided. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Category: piperazines

The Article related to infectious disease drug screening pluripotent stem cell macrophage, Placeholder for records without volume info and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On November 1, 2021, Temps, Carolin; Lietha, Daniel; Webb, Emily R.; Li, Xue-Feng; Dawson, John C.; Muir, Morwenna; Macleod, Kenneth G.; Valero, Teresa; Munro, Alison F.; Contreras-Montoya, Rafael; Luque-Ortega, Juan R.; Fraser, Craig; Beetham, Henry; Schoenherr, Christina; Lopalco, Maria; Arends, Mark J.; Frame, Margaret C.; Qian, Bin-Zhi; Brunton, Valerie G.; Carragher, Neil O.; Unciti-Broceta, Asier published an article.Application of 380843-75-4 The title of the article was A conformation selective mode of inhibiting SRC improves drug efficacy and tolerability. And the article contained the following:

Despite the approval of several multikinase inhibitors that target SRC and the overwhelming evidence of the role of SRC in the progression and resistance mechanisms of many solid malignancies, inhibition of its kinase activity has thus far failed to improve patient outcomes. Here we report the small mol. eCF506 locks SRC in its native inactive conformation, thereby inhibiting both enzymic and scaffolding functions that prevent phosphorylation and complex formation with its partner FAK. This mechanism of action resulted in highly potent and selective pathway inhibition in culture and in vivo. Treatment with eCF506 resulted in increased antitumor efficacy and tolerability in syngeneic murine cancer models, demonstrating significant therapeutic advantages over existing SRC/ABL inhibitors. Therefore, this mode of inhibiting SRC could lead to improved treatment of SRC-associated disorders. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Application of 380843-75-4

The Article related to breast cancer src conformation lymphocyte ecf506 antiproliferative, Placeholder for records without volume info and other aspects.Application of 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Dong, Kui; Zhao, Chuang-Yuan; Wang, Xiao-Ju; Wu, Li-Zhu; Liu, Qiang published an article in , the title of the article was Bioinspired Selective Synthesis of Heterodimer 8-5′ or 8-O-4′ Neolignan Analogs.Safety of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone And the article contains the following content:

The bioinspired synthesis of heterodimer neolignan analogs is reported by single-electron oxidation of both alkenyl phenols and phenols individually, followed by a combination of the resultant radicals. This oxidative radical cross-coupling strategy can afford heterodimer 8-5′ or 8-O-4′ neolignan analogs selectively with the use of air as the terminal oxidant and copper acetate as the catalyst at room temperature The experimental process involved the reaction of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone(cas: 67914-60-7).Safety of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone

The Article related to neolignan heterodimer preparation oxidative radical cross coupling, Placeholder for records without volume info and other aspects.Safety of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On November 25, 2021, Schiffer, Charles A. published an article.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was Asciminib for CML: same target, new arrow. And the article contained the following:

The outlook for patients with chronic phase chronic myelogenous leukemia (CML) has improved dramatically since the development in the late 1990s of oral tyrosine kinase inhibitors (TKIs) targeting the ATP binding site of the BCR-ABL1 oncoprotein. Here, the authors address the management of patients in chronic phase previously treated with ≥ 2 TKIs in a randomized trial comparing asciminib and bosutinib, which is approved for use in this patient population. Ascinimib (previously known as ABL001) is a small mol. which binds to the myristoyl pocket located at a different site on the BCR-ABL1 protein, producing a conformational change that inhibits downstream signaling. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to asciminib bosutinib anticancer agent chronic myelogenous leukemia, Placeholder for records without volume info and other aspects.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 28, 2018, Kamata, Ryo; Nakajima, Daisuke; Shiraishi, Fujio published an article.HPLC of Formula: 67914-60-7 The title of the article was Agonistic effects of diverse xenobiotics on the constitutive androstane receptor as detected in a recombinant yeast-cell assay. And the article contained the following:

The constitutive androstane receptor (CAR) is a nuclear receptor and transcription factor regulating proteins involved in xenobiotic metabolism Agonist activation of the CAR can trigger metabolic activation and toxification as well as detoxification and clearance; accordingly, xenobiotic substances acting as CAR ligands may pose a threat to human and animal health. The authors used yeast cells transduced with the human CAR and the response pathway to measure the CAR-agonistic activities of 549 synthetic or natural compounds: 216 of the tested compounds exhibited CAR-agonistic effects. Eighty-four percent of CAR-activating compounds were aromatic compounds, and >65% of these active compounds were aromatic hydrocarbons, bisphenols, monoalkyl phenols, phthalates, styrene dimers, di-Ph ethers, organochlorines, and organophosphates. The ten most potent compounds were 4-tert-octylphenol (4tOP; reference substance), 4-nonylphenol, diethylstilbestrol, benzyl Bu phthalate, 2-(4-hydroxyphenyl)-2,4,4-trimethylchroman, o,p’-DDT, methoxychlor, di-Pr phthalate, hexestrol, and octachlorostyrene. The activities of these nine non-reference compounds exceeded 10% of the 4tOP activity. Anal. of para-monoalkyl phenols suggests that branching of the alkyl group and chlorination at the ortho position raises potency. This study provides critical information for identifying the potential of CAR-mediated toxic hazards and for understanding the relevant mechanism. The experimental process involved the reaction of 1-(4-(4-Hydroxyphenyl)piperazin-1-yl)ethanone(cas: 67914-60-7).HPLC of Formula: 67914-60-7

The Article related to xenobiotic constitutive androstane receptor, alkyl phenol, bisphenol, constitutive androstane receptor, organochlorine, recombinant yeast, styrene dimer, Toxicology: Methods (Including Analysis) and other aspects.HPLC of Formula: 67914-60-7

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics